Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GOSS – Gossamer Bio, Inc.

Float Short %

10.26

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

EPS Last/This Y

-0.43

EPS This/Next Y

0.2

Price

2.35

Target Price

7.75

Analyst Recom

1.44

Performance Q

101.72

Relative Volume

1.9

Beta

1.94

Ticker: GOSS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25GOSS1.850.040.1458717
2025-07-28GOSS1.9850.040.0058958
2025-07-29GOSS1.960.040.0059059
2025-07-30GOSS2.070.030.0070691
2025-07-31GOSS2.040.030.0069895
2025-08-01GOSS20.030.0069675
2025-08-04GOSS2.160.030.0272129
2025-08-05GOSS2.150.030.0172424
2025-08-06GOSS1.980.030.0182718
2025-08-07GOSS1.720.030.1383461
2025-08-08GOSS1.7650.030.0183402
2025-08-11GOSS1.7350.030.0283658
2025-08-12GOSS1.9250.030.0083901
2025-08-13GOSS1.980.030.0483980
2025-08-14GOSS1.9550.030.0484073
2025-08-15GOSS1.9650.030.0084193
2025-08-18GOSS1.9950.030.0076175
2025-08-19GOSS1.9250.030.6476070
2025-08-20GOSS1.9450.030.1876097
2025-08-21GOSS2.1650.030.2976184
2025-08-22GOSS2.3450.040.0076556
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25GOSS1.84-183.8-100.8-0.69
2025-07-28GOSS1.99-183.8-108.3-0.69
2025-07-29GOSS1.96-183.6-94.2-0.69
2025-07-30GOSS2.08-183.6-105.0-0.69
2025-07-31GOSS2.04-183.6-92.5-0.69
2025-08-01GOSS2.00-183.6-92.5-0.69
2025-08-04GOSS2.17-183.6-109.0-0.69
2025-08-05GOSS2.16-183.6-94.9-0.69
2025-08-06GOSS1.97-183.6-82.1-0.69
2025-08-07GOSS1.74-183.613.1-0.69
2025-08-08GOSS1.76-183.6-6.4-0.69
2025-08-11GOSS1.74-39.3-2.0-0.73
2025-08-12GOSS1.92-39.3-18.2-0.73
2025-08-13GOSS1.97-39.3-6.2-0.73
2025-08-14GOSS1.96-39.3-4.3-0.73
2025-08-15GOSS1.97-39.3-6.2-0.68
2025-08-18GOSS2.00-35.7-8.3-0.68
2025-08-19GOSS1.92-35.7-0.6-0.68
2025-08-20GOSS1.94-35.7-6.9-0.68
2025-08-21GOSS2.16-35.7-20.6-0.68
2025-08-22GOSS2.35-35.7-16.8-0.68
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25GOSS0.000.719.92
2025-07-28GOSS0.007.039.92
2025-07-29GOSS0.007.039.92
2025-07-30GOSS0.007.039.92
2025-07-31GOSS0.007.039.92
2025-08-01GOSS0.007.039.92
2025-08-04GOSS0.006.319.92
2025-08-05GOSS0.006.319.92
2025-08-06GOSS0.006.319.92
2025-08-07GOSS0.006.319.92
2025-08-08GOSS0.006.319.92
2025-08-11GOSS0.007.319.92
2025-08-12GOSS0.007.3110.26
2025-08-13GOSS0.007.3110.26
2025-08-14GOSS0.007.3110.26
2025-08-15GOSS0.007.3110.26
2025-08-18GOSS0.008.8110.26
2025-08-19GOSS0.008.8110.26
2025-08-20GOSS0.068.8110.26
2025-08-21GOSS0.068.8110.26
2025-08-22GOSS0.068.8110.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

0.06

Institutional Transactions

8.81

Beta

1.94

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

8

Fair Value

Quality Score

9

Growth Score

24

Sentiment Score

90

Actual DrawDown %

84.6

Max Drawdown 5-Year %

-96.8

Target Price

7.75

P/E

Forward P/E

PEG

P/S

13.22

P/B

P/Free Cash Flow

EPS

-0.61

Average EPS Est. Cur. Y​

-0.68

EPS Next Y. (Est.)

-0.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-344.81

Relative Volume

1.9

Return on Equity vs Sector %

276.2

Return on Equity vs Industry %

289.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-16.8
Gossamer Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 144
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading